-- 
Israel Stocks: Delek Real Estate, Delta-Galil, Medigus, Teva

-- B y   S h o s h a n n a   S o l o m o n
-- 
2011-10-11T16:30:33Z

-- http://www.bloomberg.com/news/2011-10-11/israel-stocks-delek-real-estate-delta-galil-medigus-teva.html
Israel ’s TA-25 Index climbed 0.6
percent to 1,084.73 at the 4:30 p.m. close in Tel Aviv, the
highest level since Sept. 21. The measure gained 3.3 percent in
a shortened trading week. Israeli markets will be closed until
Oct. 16 for a holiday.  Investors traded about 1.64 billion shekels ($446 million)
of shares and convertible securities in Tel Aviv today,
according to bourse data.  The following stocks rose or fell today. Symbols are in
parentheses.  Delek Real Estate Ltd. (DLKR)   soared to the highest
since Sept. 1, surging 15 percent to 0.217 shekel. The property
company said that over the past few weeks a number of parties
have indicated an interest to invest in the company. Calcalist
reported earlier that a Citigroup Inc. real-estate fund was
interested in taking a stake.  Delta-Galil Industries Ltd. (DELT)   jumped the most since
January 2010, increasing 8.1 percent to 21.62 shekels. The
lingerie maker is in talks to buy the denim operations of Jones
Group Inc. for $350 million to $400 million.  Medigus Ltd. (MDGS)   rose to the highest since March 15,
gaining 2.9 percent to 1.088 shekels. The maker of endoscopic
procedures said it developed a disposable nasogastric feeding
tube with a camera.  Prolor Biotech Inc. (PBTH)   gained the most since Sept.
25, rising 3.6 percent to 15.06 shekels. The biopharmaceutical
company received a U.S. patent for its CTP-modified interferons.  Teva Pharmaceutical Industries Ltd. (TEVA)   climbed to
the highest in more than a week, adding 1.6 percent to 140.20
shekels. The Federal Trade Commission approved the world’s
largest generic drugmaker’s planned purchase of Cephalon Inc.  The European Commission is expected to approve the
acquisition, Reuters reported yesterday, citing an unnamed
person. Denise Bradley, a U.S-based spokeswoman for Teva, said
the company hadn’t received the approval yet.  To contact the reporter on this story:
Shoshanna Solomon in  Tel Aviv  at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  